NASDAQ
ALPN

Alpine Immune Sciences Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Alpine Immune Sciences Inc Stock Price

Vitals

Today's Low:
$12.24
Today's High:
$13.13
Open Price:
$12.9
52W Low:
$4.82
52W High:
$10.3
Prev. Close:
$12.85
Volume:
140209

Company Statistics

Market Cap.:
$375.58 million
Book Value:
4.136
Revenue TTM:
$31.82 million
Operating Margin TTM:
-167.06%
Gross Profit TTM:
$-35299000
Profit Margin:
-169.92%
Return on Assets TTM:
-12.65%
Return on Equity TTM:
-35.47%

Company Profile

Alpine Immune Sciences Inc had its IPO on 2015-06-17 under the ticker symbol ALPN.

The company operates in the Healthcare sector and Biotechnology industry. Alpine Immune Sciences Inc has a staff strength of 85 employees.

Stock update

Shares of Alpine Immune Sciences Inc opened at $12.9 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $12.24 - $13.13, and closed at $12.28.

This is a -4.44% slip from the previous day's closing price.

A total volume of 140,209 shares were traded at the close of the day’s session.

In the last one week, shares of Alpine Immune Sciences Inc have slipped by -4.81%.

Alpine Immune Sciences Inc's Key Ratios

Alpine Immune Sciences Inc has a market cap of $375.58 million, indicating a price to book ratio of 1.5237 and a price to sales ratio of 9.423.

In the last 12-months Alpine Immune Sciences Inc’s revenue was $31.82 million with a gross profit of $-35299000 and an EBITDA of $-52564000. The EBITDA ratio measures Alpine Immune Sciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Alpine Immune Sciences Inc’s operating margin was -167.06% while its return on assets stood at -12.65% with a return of equity of -35.47%.

In Q3, Alpine Immune Sciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 1.7%.

Alpine Immune Sciences Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-1.76 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alpine Immune Sciences Inc’s profitability.

Alpine Immune Sciences Inc stock is trading at a EV to sales ratio of 1.3846 and a EV to EBITDA ratio of -0.8567. Its price to sales ratio in the trailing 12-months stood at 9.423.

Alpine Immune Sciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$291.60 million
Total Liabilities
$68.46 million
Operating Cash Flow
$25.79 million
Capital Expenditure
$55000
Dividend Payout Ratio
0%

Alpine Immune Sciences Inc ended 2024 with $291.60 million in total assets and $0 in total liabilities. Its intangible assets were valued at $291.60 million while shareholder equity stood at $182.01 million.

Alpine Immune Sciences Inc ended 2024 with $0 in deferred long-term liabilities, $68.46 million in other current liabilities, 44000.00 in common stock, $-205097000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $126.63 million and cash and short-term investments were $248.86 million. The company’s total short-term debt was $5,265,000 while long-term debt stood at $0.

Alpine Immune Sciences Inc’s total current assets stands at $253.24 million while long-term investments were $28.02 million and short-term investments were $122.24 million. Its net receivables were $677000.00 compared to accounts payable of $3.24 million and inventory worth $0.

In 2024, Alpine Immune Sciences Inc's operating cash flow was $25.79 million while its capital expenditure stood at $55000.

Comparatively, Alpine Immune Sciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$12.28
52-Week High
$10.3
52-Week Low
$4.82
Analyst Target Price
$14.4

Alpine Immune Sciences Inc stock is currently trading at $12.28 per share. It touched a 52-week high of $10.3 and a 52-week low of $10.3. Analysts tracking the stock have a 12-month average target price of $14.4.

Its 50-day moving average was $12.42 and 200-day moving average was $9.21 The short ratio stood at 9.15 indicating a short percent outstanding of 0%.

Around 668.4% of the company’s stock are held by insiders while 8954.5% are held by institutions.

Frequently Asked Questions About Alpine Immune Sciences Inc

The stock symbol (also called stock or share ticker) of Alpine Immune Sciences Inc is ALPN

The IPO of Alpine Immune Sciences Inc took place on 2015-06-17

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$237
-23.3
-8.95%
$53.11
0.59
+1.12%
$0.35
-0.02
-5.24%
$2.27
-0.01
-0.25%
$34.59
-0.02
-0.06%
Amark Preci (AMRK)
$34.55
-0.85
-2.4%
$17.94
-1.06
-5.58%
$7.18
-0.37
-4.9%
$553.2
-30.35
-5.2%
$22.6
0.11
+0.49%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Address

188 East Blaine Street, Seattle, WA, United States, 98102